Biomarker testing is an integral part of personalized genome medicine medicine.  Number of actionable biomarkers for solid tumours is rapidly expanding. Targeted NGS is a new gold standard, replacing single analyte technologies for identification of DNA sequence  variants and fusion transcripts associated with sensitivity to targeted therapies.  Oncomine Precision Assay on the Ion Torrent Genexus System is an automated platform for rapid detection of DNA hospot variants and targeted fusions. This presentation will describe our laboratory experience with validation and implementation of the Oncomine Precision Assay for solid tumour testing,  focusing on non-small cell lung cancer.